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Abstract: The ‘onco-receptor’ MET (Hepatocyte Growth Factor Receptor) is involved in the activation
of the invasive growth program that is essential during embryonic development and critical for
wound healing and organ regeneration during adult life. When aberrantly activated, MET and
its stroma-secreted ligand HGF (Hepatocyte Growth Factor) concur to tumor onset, progression,
and metastasis in solid tumors, thus representing a relevant target for cancer precision medicine.
In the vast majority of tumors, wild-type MET behaves as a ‘stress-response’ gene, and relies
on ligand stimulation to sustain cancer cell ‘scattering’, invasion, and protection form apoptosis.
Moreover, the MET/HGF axis is involved in the crosstalk between cancer cells and the surrounding
microenvironment. Pancreatic cancer (namely, pancreatic ductal adenocarcinoma, PDAC) is an
aggressive malignancy characterized by an abundant stromal compartment that is associated with
early metastases and resistance to conventional and targeted therapies. Here, we discuss the role
of the MET/HGF axis in tumor progression and dissemination considering as a model pancreatic
cancer, and provide a proof of concept for the application of dual MET/HGF inhibition as an adjuvant
therapy in pancreatic cancer patients.
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1. The Hepatocyte Growth Factor Receptor (MET) and Its Ligand (HGF)
MET was originally identified from a chemically transformed human osteosarcoma cell line as an
oncogene resulting from the chromosomal rearrangement of the MET tyrosine kinase domain with
a dimerization domain (TRP-MET) [1]. The MET gene was then mapped on chromosome 7q21-31
and its product identified as the tyrosine-kinase transmembrane protein, which is the high-affinity
receptor for the Hepatocyte Growth Factor (HGF) [2,3]. MET is a heterodimeric protein made of two
disulphide-linked chains of 50 kDa (α) and 145 kDa (β) [4]. The extracellular portion of MET has
a modular structure. It contains: (i) an N-terminal SEMA domain (found also in semaphorins and
plexins [5]) composed of 500 residues and characterized by a seven-bladed β-propeller structure [6];
(ii) a PSI domain (present also in Plexins, Semaphorins, and Integrins), comprising about 50 residues
and containing four disulfide bonds; and (iii) four IPT domains (Immunoglobulin-like fold present
also in Plexins and Transcription factors) [7,8]. The intracellular portion of MET includes: (i) a
juxtamembrane region, which acts as negative regulator of the kinase activity [9,10]; (ii) a tyrosine
kinase domain, which includes the major phosphorylation site that, following receptor dimerization
and transphosphorylation, triggers the signaling cascade; and (iii) a C-terminal tail, which acts
as multifunctional docking sites for the recruitment and activation of several intracellular signal
transducers and adaptors [11,12] (Figure 1A).
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HGF was identified by two independent studies as a mitogen for hepatocytes [13–15] and
as a fibroblast-secreted scatter factor (SF) able to induce dissociation and motility of epithelial
cells [16]. In 1991, HGF and SF were recognized as the same protein responsible for the induction of
a variety of biological responses through the binding to MET [2,17]. HGF (Figure 1B) is a member
of the plasminogen-related growth factor family, and it is synthesized as an inactive single-chain
precursor (pro-HGF), which is proteolytically processed in the extracellular environment to generate
the biologically active molecule [13,18]. The resulting mature HGF is a 90 kDa heterodimer consisting
of two chains of 69 kDa (α) and 34 kDa (β), respectively, linked by a disulphide bridge. The α
subunit includes an N-terminal hairpin loop and four kringle domains; the β subunit consists of
a serine protease homology domain lacking enzymatic activity [19]. The HGF–MET interaction is
highly complex, and engages different sites both on the ligand and the receptor. The α-chain of
HGF binds MET at high affinity, interacting with both the IPT [20] and the SEMA [21,22] domains
of the receptor. Conversely, the HGF β-chain binds the MET SEMA domain at low affinity [6,23].
Importantly, the cooperation between the two chains is necessary for HGF biological activity; while
the α-chain is sufficient for MET binding, the β-chain is required for MET activation [24]. In particular,
conformational changes occurring in the β-chain of HGF upon proteolytic cleavage allow for allosteric
stabilization of the MET/HGF interaction and are critical for activity [25] (Figure 1B).
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Figure 1. Schematic structure of MET and HGF. (A) MET structure. SEMA, a seven-bladed β-propeller
domain shared with Semaphorins and Plexins; PSI, a cysteine-rich domain present also in Plexins,
Semaphorins, and Integrins; IPT, four immunoglobulin-like domains present also in Plexins and
Transcription factors; JM, juxtamembrane domain, a region containi g residues that act as negative
regul tors of the kin se activity; TK, tyros ne kinase doma en wed with enzymatic activity; tail,
a C-terminal domain cont ining the multifunctiona dock ng site. I gre n the α-c ain, in brown
the β-chain of MET. The grey line represents the cell membrane. (B) HGF structure. HL, hairpin
loop; K1–K4, kringle domains; SPH, serine-protease homology domain, devoid of protease activity.
In blue the α-chain, in red the β-chain of HGF. S-S, disulphide bond linking the α- and β-chains of the
two molecules.
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2. MET/HGF Signaling in the Physiological Context
The interaction between HGF and MET induces receptor dimerization, which results in
trans-phosphorylation of the two tyrosine residues Y1234 and Y1235 within the catalytic domain [26],
and the subsequent phosphorylation of tyrosines Y1349 and Y1356 within the C-terminal docking site,
allowing for the recruitment of signal-relay molecules [11]. MET activation spurs a complex network
of unconventional and pleiotropic intracellular signals that control a multifaceted genetic program,
known as ‘invasive growth’ [27], that promotes cell proliferation, scattering, motogenesis, and survival.
In epithelial cells, MET activation is followed by the acquisition of polarity and tubule formation [28,29].
This program is pivotal during embryonic development [30] and plays an important role in adult life,
regulating tissue homeostasis, wound healing, and organ regeneration [31–34] (Figure 2).
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In the early phases of mouse embryogenesis, HGF and its receptor MET are co-expressed in 
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Figure 2. MET signaling in the physiological context. Upon MET activation, signal-relay molecules are
recruited to the receptor, resulting in activation of the MAPK (mitogen-activated protein kinase)/Akt
signaling pathways. This process controls the genetic program known as ‘invasive growth’ that in the
physiological context plays a pivotal role in embryogenesis and in tissue homeostasis during adult
life. PI3K, phosphoinositide 3-kinase; GRB2, growth factor receptor-bound protein 2; STAT, signal
transducer and activator of transcription protein; GAB1, GRB2-associated-binding protein 1; PLC-
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In the early phases of mouse embryogenesis, HGF and its receptor MET are co-expressed
in endodermal and mesodermal structures long the r stro-caudal axis [35]. However, during
organogenesi , autocrine signaling stops in favor of a paracrine mode of activation, in which MET,
expressed b epithelial and myoblast progenitors, is stimulated by the HGF produced by mesenchymal
cells [36]. This paracrine loop is able to conjugate proliferative and anti-apoptotic stimuli with a
strong motogenic activity into a single ‘invasive growth’ program that is necessary for embryonic
development. In the adult, the signaling program activated by MET and HGF during organogenesis is
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exploited in the presence of wounds and tissue damage. In this context, pro-inflammatory cytokines,
such as interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor-α (TNFα), induce HGF
and MET overexpression, while the stroma contributes to HGF activation by upregulating the
transcription of proteases involved in proHGF processing [37,38]. HGF induces a re-organization
of the focal adhesion components, actin stress fibers, and microtubules by eliciting the recruitment
of the intracellular effectors GAB1, Akt, ERK (extracellular signal-regulated kinase 1), and RhoA
(Ras homolog gene family member A), and it promotes the proliferation and migration of epithelial
cells at wound edges [39]. In the liver and kidney, persistent damage leads to the deposition of
extracellular matrix by myofibroblasts (fibrosis), sustained by TGF-β (transforming growth factor-β)
upregulation [40]. This process is antagonized by HGF-mediated MET activation, which leads to
downregulation of TGF-β transcription and Smad inhibition through ERK [41,42]. Moreover, HGF
sustains the proliferation of renal epithelial cells by activating the Ras-dependent MAPK pathway and
the PI3K-AKT pathways, and protects them from apoptosis by upregulating anti-apoptotic effectors,
such as BCL-2 (B-cell lymphoma-2) [43]. In vivo, liver damage leads to a sharp increase in HGF
production, which provides mitogenic and anti-apoptotic stimuli for organ repair [44]. Accordingly,
organ reconstitution after hepatectomy is abrogated in MET conditional knock-out mice [34]. Finally,
the MET/HGF pathway plays a relevant role in cardiovascular protection in response to both acute and
chronic damage [45]. After ischemic injury, for example, MET activation provides strong anti-apoptotic
stimuli for cardiomyocytes through the PI3K/AKT and MAPK pathways [46].
3. MET/HGF Signaling in Cancer
Unfortunately, the same highly regulated events that mediate MET/HGF biological responses
during embryo development and contribute to maintain tissue homeostasis in the adult are unleashed
in cancer. The first evidence of a link between MET and human oncogenesis was obtained from
the observation of a number of germline MET mutations in patients with hereditary papillary renal
cell carcinomas (HPRCC) [47]. Since then, altered MET functions were identified as a hallmark of
several cancer types, including carcinomas, sarcomas, and brain tumors, and may occur through
gene amplification, deletions, mutations, receptor overexpression, or disruption of normal paracrine
signaling [48–50].
In a limited number of tumors, MET genetic lesions—either mutations [47] or
amplifications [51]—lead to the constitutive activation of MET. Oncogenic mutations are concentrated
in domains critical for ligand binding or receptor signaling. In the first case, mutations occur in
the extracellular SEMA domain, likely affecting the ligand–receptor interaction or the ability of
MET to dimerize, and have been detected in lung, gastric, and breast cancer [48], as well as in
cancers of unknown primary (CUPs) [52]. In the second case, point mutations or deletions affect the
juxtamembrane domain of MET—inducing sustained signaling by attenuating receptor ubiquitination
and degradation—or the catalytic domain of the receptor, causing MET hyper-activation [49,53].
Both cases result in prolonged and uncontrolled receptor signaling, which generates a cell autonomous
mechanism mostly independent of ligand binding. Similar aberrant activation may derive from gene
amplification. Such MET genetic lesions act as drivers of malignant transformation, and confer a
growth advantage to tumor cells [54]. In this context, cancer cells depend on MET signaling for their
growth and survival, a phenomenon that is common to other tyrosine kinase receptors and that has
been indicated as ‘oncogene addiction’ [55]. As a consequence, blockade of the MET pathway results
in inhibition of tumor growth.
The generation of a MET/HGF autocrine loop by anomalous co-expression of ligand and
receptor in the same cell is another way by which cancer cells may achieve continuous MET
activation. This mechanism has been described mainly in non-epithelial human tumors, such as
osteosarcomas [56], glioblastomas [57], and multiple myelomas [58]. Tumors of mesenchymal origin,
such as osteosarcomas and rhabdomyosarcomas that physiologically express HGF, can acquire
an aberrant expression of MET leading to the establishment of an autocrine loop that sustains
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constitutive activation of the signaling pathway [56]. Similarly, tumors deriving from cells that
physiologically express MET, including glioblastomas and breast carcinomas, can acquire anomalous
HGF expression [59,60]. The presence of autocrine loops is indicative of aggressive cancers with a poor
prognosis [59].
However, in the vast majority of tumors, aberrant MET signaling derives from the upregulation of
wild-type MET or HGF transcription, leading to receptor and/or ligand overexpression [61,62], or from
extensive proteolytic conversion of pro-HGF stored in the extracellular matrix, resulting in unrestrained
availability of biologically active HGF. In such conditions, the HGF secreted by the reactive tumor
stroma acts on cancer cells expressing MET to promote pro-invasive and anti-apoptotic responses.
MET or HGF overexpression frequently arises as a consequence of transcriptional upregulation in
response to adverse environmental cues, such as inflammation and hypoxia. In fact, both MET and
HGF gene promoters contain binding sites for transcription factors, including hypoxia-inducible factor
1α (HIF1α) and nuclear factor-κB (NF-κB), that are induced or activated by stress conditions [50].
Differently from the context of ‘oncogene addiction’—where aberrant receptor signaling originates
from a genetic lesion and drives cancer initiation—here, wild-type MET activation represents a strategy
harnessed by otherwise transformed tumor cells to overcome barriers to their progression and to
boost their malignant phenotype. This condition is defined as ‘oncogene expedience’ [63]: cancer
cells exploit the invasive growth program elicited by MET to increase their survival, motility, and
invasiveness. In line with this assumption, wild-type MET overexpression is frequently associated
with highly aggressive tumors, in which ‘pioneer’ cells exploit the invasive growth program elicited
by MET to detach from the primary site, invade distant tissues, and establish metastatic lesions [27].
In light of these considerations, therapies targeting the MET/HGF pathway in a context of expedience
may impair the survival and the ability to disseminate of cancer cells, but are not expected to reduce
tumor growth.
4. MET/HGF Signaling in the Crosstalk between Cancer Cells and the Tumor Microenvironment
The contribution of the tumor microenvironment (TME) to cancer progression is becoming
increasingly relevant. It is now well-established that the malignant phenotype does not develop
in a strictly cell-autonomous way, but through a complex interplay that takes place between the
tumor cells and the surrounding stroma [64]. Tumors are complex tissues where cancer cells coexist
with several non-malignant cells that produce a rich extracellular matrix (ECM) and a variety of
molecular effectors. The cellular fraction of TME is composed by a multitude of stromal cell types,
including fibroblasts, pericytes, endothelial and mesenchymal cells, as well as cells of the immune
system [64]. Non-malignant stromal cells are recruited and corrupted by cancer cells to produce
cytokines, chemokines, growth factors, and matrix remodeling enzymes, resulting in a complex and
dynamic network that often retains a tumor-promoting activity at all stages of carcinogenesis [65].
Cancer-associated fibroblasts (CAFs) are often referred to as myofibroblasts due to the acquisition
of a multi-spindled shape and positivity for α-smooth-muscle actin (α-SMA). CAFs produce higher
levels of tumor-promoting factors, such as HGF, FGF, TGFβ, PDGF, VEGF, and EGF, as compared
to normal fibroblast; these factors act in a paracrine manner on the cognate receptors expressed on
adjacent tumor cells [66–68]. In addition, CAFs secrete abnormal ECM components, such as tenascin,
periostin, SPARC, and collagen, which overall contribute to a more rigid and contractile ECM that
favors tumor growth and survival [69]. In fact, TME-associated ECM is different from that of normal
tissues: in particular, elevated collagen crosslinking causes alterations of its biochemical properties,
increasing tissue rigidity. The ECM is composed of a variety of macromolecules with distinctive
properties, including proteins, glycoproteins, proteoglycans, and polysaccharides, and represents
a dynamic scaffold for the growth and invasion of tumor cells [70,71]. Moreover, the activity of
matrix metalloproteases (MMPs) contributes to ECM remodeling, inducing the release of chemokines,
growth factors, and pro-angiogenic factors [72,73]. Altogether, the activated stroma creates a dense
fibrosis called ‘desmoplastic reaction’ around the tumor, which constitutes a physical obstacle for
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drug penetration and affects tumor vascularization [74]. Among the plethora of factors secreted in the
tumor microenvironment, HGF plays a relevant pro-malignant role, triggering cancer cell invasion
and metastatic dissemination via paracrine stimulation of its receptor on tumor cells. MET activation
further stimulates HGF production by CAFs, thus establishing a dynamic bidirectional ‘tumor-host
signaling program’ [75] (Figure 3).
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Figure 3. The dynamic bidirectional tumor/stroma interaction. Cancer-associated fibroblasts (CAFs)
secrete pro-HGF that is converted in the active mature form by enzymes acting in the tumor
microenvironment. Tumor cells can influence CAF activity by mechanisms that have not yet been
completely elucidated. The fibrotic components of the extracellular matrix are depicted in grey.
The malignant behavior of cancer cells is nurtured by the collateral pro-angiogenic activity of
the MET/HGF axis in endothelial (ECs) and stromal cells [76]. MET upregulation in ECs is required
to promote the early steps of angiogenesis, in which ECs change shape, invade the extracellular
matrix, and proliferate [77]. Furthermore, HGF stimulates angiogenesis both directly—by binding to
its receptor on the surface of endothelial cells—and indirectly—by prompting non-EC populations to
produce pro-angiogenic factors, such as vascular endothelial growth factor (VEGF)-A [78]. Overall,
MET and HGF concur to increase neovascularization, tumor expansion, and the release of neoplastic
emboli into the bloodstream, regardless of the state of MET activation in cancer cells.
Furthermore, MET pathway activation also influences macrophage polarization, inducing a shift
of their phenotype from an immunological active phenotype (M1) to a trophic, growth-stimulating
state (M2), promoting an immunosuppressive environment [50,79].
In order to allow for the execution of the multifaceted metastatic process, a favorable
microenvironment around the tumor tissue is mandatory, as well as plasticity and migration of
cancer cells. Metastases arise from a selected cell subpopulation that resides in the heterogeneous
primary tumor [80]. The acquisition of a metastatic phenotype requires the aberrant execution of
a biological plan, including the activation of the invasive growth program, in which cancer cells
acquire the ability to disrupt cell-to-cell interactions, migrate through the extracellular matrix, spread
through lymphatic or hematopoietic vessels, and finally extravasate, survive, and proliferate in tissues
other than their site of origin [61]. The MET/HGF pathway acts as a key player at multiple stages
during the development of the metastatic disease, from cellular dissociation within the primary
tumor to cellular re-association within the metastatic niche [27]. For instance, HGF triggers the
destabilization of cell–cell adherents junctions, shapes cytoskeleton reorganization, modulates integrin
functions, and it stimulates the MMP-mediated proteolysis of ECM [27,50]. Recently, the invasive
growth concept has been redefined to incorporate the process of epithelial-to-mesenchymal transition
(EMT) [50]. EMT is a reversible, plastic condition through which cancer cells undergo a global
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change in cell architecture and phenotype: this confers the ability to spread out from the native tissue
and to establish tumor colonies in distant organs [81]. EMT displays a number of analogies with
physiological processes, such as re-epithelization during wound healing and cell migration during
embryonic development [82]. The role of MET in organogenesis and tubule formation has been
thoroughly studied and well-described: after HGF stimulation, cells form protruding branches and
undergo a partial EMT, which results in invasive, spindle-shaped cells that form long cytoplasmic
extensions in the surrounding matrix [83]. The cells within the extensions must resist anoikis to
divide and arrange in rows. Ultimately, cells re-differentiate to the epithelial phenotype by restoring
polarity, and subsequently the tubules evolve into solid cords with a continuous lumen [83]. The same
MET/HGF-dependent mechanism described in a physiological context is exploited by cancer cells
to disseminate from the tissue of origin and to colonize a different organ [84]. Migrating cancer cells
seem to evade anoikis by MET-dependent upregulation of the cytoskeleton adhesion receptors, which
allows them to interact with the new surrounding cells and to elude apoptosis [85].
5. MET/HGF Signaling in Pancreatic Cancer
Since the pioneer studies published in 1995 [86], the MET/HGF system has gained growing
attention with respect to its role in the pathogenesis of pancreatic cancer (for a review see [87]).
About 94% of these cancers develop from the exocrine tissues and are classified in four subtypes: ductal
adenocarcinoma, acinar cell carcinoma, intraductal papillary-mucinous neoplasm, and mucinous
cystic neoplasm [88]. Pancreatic Ductal Adenocarcinoma (PDAC) accounts for the majority of
cases, representing an aggressive malignant disease with a 5-year survival rate lower than 5% [89].
Multifactorial reasons are responsible for this extremely morbid outcome, such as diagnosis at late
stage, rapid metastatic progression, and resistance to conventional therapy. PDAC is characterized by
an intense stromal desmoplastic reaction [90] that accounts for about 80% of the cancer nodule [91].
This fibrotic stroma is produced mainly by a special type of CAFs, the activated pancreatic stellate
cells (PSCs), which are entwined into the acinar cells of the pancreas [90]. In tumorigenic conditions,
a prolonged activation of PSCs and the extensive crosstalk with cancer cells perpetuate the desmoplastic
reaction, leading to the deposition of excessive amounts of ECM proteins around malignant cells.
The fibrous layer may restrict blood flow, oxygen availability, and the delivery of chemotherapeutic
agents, inducing, respectively, metabolic switches, tissue hypoxia, and drug resistance. Additionally,
the dense stromal compartment also represents a reservoir of cytokines and growth factors. An example
is given by HGF, which is secreted, accumulated, and activated within the stromal tissue surrounding
the malignant cells [92]. High levels of stromal HGF have been associated with worsened overall
survival of pancreatic cancer patients [92]. Interestingly, while activating KRAS mutations followed by
mutation of p16 and loss of p53 and SMAD4 are often considered as initiating events in pancreatic
cancers [93], dysregulation of MET activity correlates with the development of an aggressive
phenotype [94]. Compared to the normal tissues, MET protein displays on average a sevenfold
increase of expression in pancreatic tumor lesions; this feature has been recently linked to the activity
of DYRK1A, a kinase involved in the regulation of the MET turn-over [95]. MET overexpression is
directly correlated to tumor grade [94,96,97], and likely supports the pro-metastatic role of TME by
sensitizing cancer cells to HGF-driven signaling [98].
Interestingly, PSCs seem to be capable of travelling within the body together with cancer cells
to colonize distant organs [99]: in patients with late-stage pancreatic cancer, CAFs were identified
within tissues containing pre-metastatic or metastatic lesions [100]. Moreover, at the metastatic site,
CAFs were found to be involved in the accumulation of a desmoplastic stroma similar to that of
primary tumors [100]. These data suggest that heterogeneous stromal signaling is required also at
the metastatic site, and support an involvement of the MET/HGF paracrine loop in the metastatic
spreading of PDAC tumors [101,102]. The MET/HGF axis has been proven to further stimulate HGF
production by mesenchymal cells, with the formation of a feed-forward loop [103]. Furthermore,
urokinase plasminogen activator (uPA), one of the factors promoting HGF maturation from an inactive
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precursor to the active form [18], was found itself to be increased by active HGF, overall resulting in a
continuous positive feedback loop amplifying both HGF and uPA [104].
The MET/HGF pathway is involved in the complex crosstalk between tumor and stroma, in
particular in the interaction between cancer cells and activated PSCs [105]. In this regard, targeting
HGF by an antibody (AMG-102) induces stromal reprogramming resulting in a reduction of collagen
deposition [106]. This result suggests that the paracrine signaling between stroma and cancer
through the MET/HGF axis is not unidirectional towards the activation of the tumor, but also favors
the activation of the stromal compartment itself, through a still unknown process that deserves
further investigation.
Although tumor resection remains the keystone of treatment for pancreatic cancer, only a small
fraction of patients are candidates for surgery at the time of diagnosis [107], as early systemic
dissemination is one of the features characterizing the disease. Currently, the treatment of choice
for advanced and metastatic pancreatic cancer is chemotherapy through gemcitabine administration,
often in combination with nab-paclitaxel. Unfortunately, most patients develop resistance after a few
weeks of treatment [108], caused either by intrinsic genetic factors (primary resistance) or by acquired
mechanisms. Among the latter, a role can be envisaged for de novo aberrant activation of signaling
pathways regulating nodal tumor–stroma interplays [108]. MET aberrant activation in pancreatic
cancer is involved in the onset of resistance to gemcitabine by different mechanisms. On one side,
MET has been identified as a marker of pancreatic cancer stem cells (CSCs) [109], and on the other
the MET/HGF axis supports the mesenchymal network [110]. Preclinical studies demonstrated that
gemcitabine-resistant PDAC cells express high levels of stem cell markers, indicating that the drug
treatment selects a subpopulation of tumor cells with stem-like features. In several solid tumors,
MET is expressed in stem/progenitor cells, fostering pro-survival and anti-apoptotic signals (MET
‘inherence’) [50]. In line with these observations, in vitro studies demonstrated that targeting the
MET pathway specifically interfered with the pancreatic CSC subpopulation, inducing apoptosis
and reducing migration of resistant cells, and synergistically interacted with anti-tumor gemcitabine
activity [111,112]. Furthermore, gemcitabine-resistant cancer cells acquire the hallmarks of EMT in
association with an increment of MET phosphorylation and the expression of the stem cell marker CD
(cluster of differentiation) [113]. In vivo, knock-out of the MET gene in a mouse model of spontaneous
pancreatic neoplasia resulted in a reduction of neoplastic cell proliferation, a predictive marker for
chemotherapeutic responses and clinical prognosis [114]. Finally, the inhibition of the tumor–stroma
interaction by MET/HGF interception induces stroma remodeling, which results in increased drug
delivery and restoration of the response to gemcitabine [106,115].
6. Concomitant Inhibition of MET and HGF: A Strategy to Interrupt the Dialogue between Tumor
and Stroma
Since the tumor microenvironment significantly contributes to cancer progression and metastasis,
and since the malignant phenotype of cancer cells may be exacerbated by the presence of
overexpressed/overactivated wild-type MET in dialogue with stromal-derived HGF, the development
of a strategy aimed at disrupting this crosstalk by concomitantly targeting receptor and ligand can
be envisaged. MET and HGF co-targeting has been previously investigated in MET-addicted tumors
and in cancers expressing a MET/HGF autocrine loop. In these contexts, the combination treatment
improves the efficacy of each monotherapy [116,117]. In a recently published work [118], we proposed
an approach for dual MET/HGF inhibition by co-administration of MvDN30, a MET-neutralizing
antibody, and decoyMETK842E, a soluble MET receptor endowed with HGF-sequestering ability.
MvDN30 is a chimeric Fab fragment that acts as a potent MET inhibitor by promoting the physical
removal of the MET receptor from the cell surface, thus shutting off MET signaling [119]. Upon binding
to MET, MvDN30 enhances the activity of receptor shedding that is mediated by the surface ADAM10
protease, supposedly by inducing conformational changes in the receptor that reveal a specific
motif recognized by the metalloprotease. As a result, the number of MET receptors exposed on
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the cell surface is strongly reduced, and soluble extracellular domains are released: they retain
functional ligand binding sites and therefore sequester the environmental HGF, preventing binding
and activation of residual receptors. To potentiate this sponge-like HGF-neutralizing activity, we
co-administered the antibody with a recombinant decoyMET, engineered by truncation of the MET
receptor immediately upstream of the transmembrane domain [120] and by insertion of a specific
amino acid substitution at position 842, where a lysine residue has been converted into a glutamic acid
(decoyMETK842E). This sequence modification, which does not affect the affinity for HGF, is sufficient
to completely abrogate the interaction between decoyMET and the antibody, thus preventing the
reciprocal neutralization of either component.
Concomitant MET/HGF targeting by the dual antibody/decoy strategy proved to be extremely
effective in blocking HGF-driven MET activation both in vitro and in vivo. Remarkable results were
obtained in a mouse model of pancreatic adenocarcinoma (PDAC) built by orthotopic injection of
human PDAC cells—expressing wild-type MET—in SCID (severe combined immunodeficient) mice
genetically modified to secrete physiological levels of human HGF (hHGF knock-in) that bypass
the problem of ligand/receptor species-specificity. In this model, the combination of MvDN30 and
decoyMETK842E targeted directly human cancer cells, strongly impairing MET phosphorylation in
primary tumors, and affecting the stromal component of primary tumors. In fact, the combo treatment
induced a reversion of the EMT phenotype (measured as vimentin/E-cadherin ratio) as well as a
decrease of activated α-SMA positive fibroblasts (Figure 4). In line with these observations, which point
to the attenuation of the invasive phenotype of the primary tumors, the dissemination of pancreatic
cancer cells was dramatically reduced. These data support a pivotal role for the MET/HGF axis in
EMT and stromal reprogramming [50], and suggest that concomitant receptor and ligand targeting
might be beneficial to impair tumor cells spreading in highly metastatic cancers, such as PDAC.
Consistent with our results, a ‘triple therapy’ (inhibition of both HGF and MET combined with
gemcitabine) has been recently shown to achieve stronger inhibition of both primary tumor growth
and metastatic dissemination compared to the single treatments or dual combinations in a mouse
model of pancreatic cancer [110].
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Figure 4. Concomitant MET/HGF targeting induces a reversion of the epithelial-to-mesenchymal
transition (EMT) phenotype as well as a decrease of activated α-SMA positive fibroblasts in an
orthotopic model of pancreatic cancer. HPAF-II cells were orthotopically injected in SCID mice
genetically modified to secrete physiological levels of human HGF (hHGF knock-in); after 2 days,
mice were divided into four groups and treated with vehicle, MvDN30 (10 mg/kg), decoyMETK842E
(10 mg/kg), or the combination of the two in a 1:1 ratio. Treatments were administered every 2 days by
intraperitoneal injection. After 5 weeks of treatment, mice were sacrificed, and primary tumors were
collected and processed for an immunofluorescence analysis. (A) E-cadherin and vimentin staining.
Bar is 50 µm. (B) α-SMA staining. Bar is 50 µm.
7. Conclusions
Activation of the MET/HGF pathway is at the same time a catalyst and a consequence of the
pro-tumoral microenvironment. TME represents a significant source of HGF, which may trigger
signaling cascades in cancer cells, thus fostering their survival and dissemination. Conversely,
MET/HGF signaling influences TME by acting directly on stromal MET-expressing cells, either
resident or attracted from blood circulation.
The results obtained with the combination of MvDN30 and decoyMETK842E suggest that the dual
decoy/antibody strategy on one side may revert the EMT process of cancer cells, and on the other
may act on the stromal component by reducing CAFs activation and ECM deposition. These results
support the hypothesis of a bidirectional signaling between stroma and cancer through the MET/HGF
axis, indicating that tumor cells might prompt the activation of the stromal compartment.
Moreover, the MET/HGF co-targeting may represent an option as an adjuvant therapy in
pancreatic cancer. The standard treatment for advanced pancreatic cancer is chemotherapy, namely
Gemcitabine alone or in combination with Nab-paclitaxel. However, often patients undergo resistance
to chemotherapy. One of the causes of PDAC chemoresistance relies on the presence of an extensive
desmoplastic reaction that surrounds the tumor, creating a physical barrier to drug penetration. In this
context, the reduction of the metastatic potential of cancer cells on one hand and the re-education of a
dysfunctional tumor microenvironment on the other could be beneficial for the treatment of pancreatic
cancer as well as of other tumors sustained by a highly active stroma, such as breast cancer [121].
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